The strategy of using Tf-decorated nanoparticles to target TfR-overexpressing tumor cells has attracted increasing attention in cancer therapy.244–246 Two Tf-guided nanoformulations, denoted as MBP-426 and CALAA-01, have shown great therapeutic potential and entered clinical trials.247. Here, TFRC is linked to neoplasm.